No annual revenue total was found in RETINALGENIX TECHNOLOGIES INC.'s SEC filings.
Retinalgenix Technologies Inc. (RTGN) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. As of Jun 30, 2026 it held $27,232 in cash and investments and $5,596 in total debt.
Revenue
—
Net income (TTM)
$-2.09M
+24.0% vs year-ago TTM
Operating cash flow (TTM)
$-477,940
+37.1% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-0.11
+25.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
18.75M
+1.3% vs prior year
Net cash
$21,636
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- RTGN (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Petaluma, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1836295
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Net income | -$2.4M | -$4.3M | -$2.1M | -$3.9M | -$2.2M |
| Diluted EPS | -$0.13 | -$0.24 | -$0.12 | — | — |
| Operating cash flow | -$558,350 | -$741,936 | -$451,661 | -$199,287 | -$1.2M |
| Total assets | $21,041 | $14,946 | $156 | $294 | $4,947 |
| Total liabilities | $2.3M | $1.5M | $1.4M | $1.1M | $469,622 |
| Stockholders' equity | -$2.3M | -$1.5M | -$1.4M | -$1.1M | -$464,675 |
| Cash and investments | $14,774 | $6,060 | — | $38 | $4,947 |
| Total debt | $6,544 | $7,532 | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Auditor change
|
Jul 15, 2026 | Jul 13, 2026 |
| 10-Q | Quarterly report | May 20, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 15, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 26, 2026 | Mar 22, 2026 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
All 114 Retinalgenix Technologies Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.